Astragaloside IV relieves passive heymann nephritis and podocyte injury by suppressing the TRAF6/NF-κb axis.
Astragaloside IV 透過抑制 TRAF6/NF-κb 軸來緩解被動 Heymann 腎炎和足細胞損傷。
Ren Fail 2024-07-31
The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy.
核苷酸感知Toll樣受體9/Toll樣受體7系統是治療IgA腎病的潛在治療靶點。
Kidney Int 2023-10-20
PLA2G12B Mediates Arachidonic Acid Metabolism through Activation of the NF-κB Pathway to Promote Membrane Nephropathy.
PLA2G12B透過啟動NF-κB途徑介導花生四烯酸代謝,促進膜性腎病。
Kidney Blood Press Res 2024-01-03
Screening of active components in <i>Astragalus mongholicus Bunge</i> and <i>Panax notoginseng</i> formula for anti-fibrosis in CKD: nobiletin inhibits Lgals1/PI3K/AKT signaling to improve renal fibrosis.
CKD抗纖維化中<i>黃芪</i>和<i>三七</i>配方中活性成分的篩選:橙皮素抑制Lgals1/PI3K/AKT信號以改善腎纖維化。
Ren Fail 2024-07-05
Astaxanthin attenuates diabetic kidney injury through upregulation of autophagy in podocytes and pathological crosstalk with mesangial cells.
虾青素透過上調足細胞中的自噬作用,以及與系膜細胞的病理性交流,減輕糖尿病腎損傷。
Ren Fail 2024-07-16
Supplemented Gegen Qinlian Decoction Formula attenuates podocyte mitochondrial fission and renal fibrosis in diabetic kidney disease by inhibiting TNF-α-mediated necroptosis, compared with empagliflozin.
補充的對秦連湯方劑通過抑制TNF-α介導的壞死性凋亡,減輕糖尿病腎病中的足細胞線粒體分裂和腎纖維化,與empagliflozin相比。
J Ethnopharmacol 2024-07-18
The immunosuppressive drug LF15-0195 acts also on glomerular lesions, by a change in cytoskeleton distribution in podocyte.
免疫抑制藥物 LF15-0195 也對腎小球病變產生作用,通過改變足細胞中的細胞骨架分佈。
Am J Nephrol 2024-07-29
Astragaloside IV attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2.
Astragaloside IV 透過抑制脂肪酸運輸蛋白-2 減輕糖尿病腎病中脂肪酸誘導的腎小管損傷。
Phytomedicine 2024-09-01